The Diagnostic Value of Signal-to-Cutoff Ratios in Architect and Alinity HIV Screening Assays: A 10-Year Experience in a Pandemic-Affected, Low-Prevalence Setting

Architect 和 Alinity HIV 筛查检测中信号截断比值的诊断价值:在受疫情影响的低流行地区开展的 10 年经验

阅读:1

Abstract

Early and accurate diagnosis of HIV remains a cornerstone of public health strategies. This study aimed to evaluate the predictive value of signal-to-cutoff (S/CO) ratios from two fourth-generation HIV screening assays (Abbott Architect and Alinity) and to analyze diagnostic trends across pre-pandemic, pandemic, and post-pandemic periods in a low-prevalence setting. We retrospectively analyzed 197,642 unique HIV screening tests conducted at Bursa Uludağ University Hospital from 2015 to 2024. Receiver operating characteristic (ROC) analysis was used to determine optimal S/CO thresholds for distinguishing true-positive results. Of the 197,642 samples screened, the overall HIV prevalence was 0.5%, with 196 cases (0.1%) confirmed as new diagnoses. The Architect assay showed an optimal S/CO threshold of ≥11.8 (sensitivity 98.3%, specificity 97.3%). The Alinity assay demonstrated 100% sensitivity and specificity at an S/CO threshold of ≥19.1. Although a temporary decline in test volume occurred in 2020, there was no statistically significant difference in confirmation rates across years. During the pandemic, newly diagnosed individuals were significantly older and had lower CD4 counts, indicating delayed diagnosis (p = 0.026 and 0.008, respectively). Men who have sex with men (MSM)-related transmission significantly increased post-pandemic (p = 0.032). S/CO ratio-guided interpretation enhances diagnostic accuracy and may reduce unnecessary confirmatory testing, especially in low-prevalence and resource-limited regions. Selecting the optimal threshold can help to ensure a timely diagnosis and optimize HIV screening algorithms.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。